Is There a Dimmer Outlook Ahead for Precision BioSciences Inc. (DTIL)? – News Heater
Home  »  Trending   »  Is There a Dimmer Outlook Ahead for Precision BioS...

Is There a Dimmer Outlook Ahead for Precision BioSciences Inc. (DTIL)?

Precision BioSciences Inc. (NASDAQ:DTIL) went down by -7.88% from its latest closing price compared to the recent 1-year high of $14.38. The company’s stock price has collected -21.24% of loss in the last five trading sessions.

Is It Worth Investing in Precision BioSciences Inc. (NASDAQ :DTIL) Right Now?

Opinions of the stock are interesting as 6 analysts out of 9 who provided ratings for Precision BioSciences Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $11.25, which is $11.48 above the current price. DTIL currently public float of 54.57M and currently shorts hold a 5.08% ratio of that float. Today, the average trading volume of DTIL was 698.18K shares.

DTIL’s Market Performance

DTIL stocks went down by -21.24% for the week, with a monthly drop of -44.93% and a quarterly performance of -68.53%, while its annual performance rate touched -83.60%. The volatility ratio for the week stands at 11.91% while the volatility levels for the past 30 days are set at 9.65% for Precision BioSciences Inc.. The simple moving average for the period of the last 20 days is -30.45% for DTIL stocks with a simple moving average of -79.31% for the last 200 days.

Analysts’ Opinion of DTIL

Many brokerage firms have already submitted their reports for DTIL stocks, with BTIG Research repeating the rating for DTIL by listing it as a “Buy.” The predicted price for DTIL in the upcoming period, according to BTIG Research is $16 based on the research report published on July 27th of the previous year 2020.

Goldman, on the other hand, stated in their research note that they expect to see DTIL reach a price target of $7, previously predicting the price at $24. The rating they have provided for DTIL stocks is “Neutral” according to the report published on April 03rd, 2020.

Stifel gave a rating of “Buy” to DTIL, setting the target price at $21 in the report published on March 05th of the previous year.

DTIL Trading at -47.54% from the 50-Day Moving Average

After a stumble in the market that brought DTIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.43% of loss for the given period.

Volatility was left at 9.65%, however, over the last 30 days, the volatility rate increased by 11.91%, as shares sank -45.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -65.14% lower at present.

During the last 5 trading sessions, DTIL fell by -21.24%, which changed the moving average for the period of 200-days by -85.00% in comparison to the 20-day moving average, which settled at $2.1210. In addition, Precision BioSciences Inc. saw -79.46% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DTIL starting from List Alan, who sale 7,775 shares at the price of $2.10 back on Apr 27. After this action, List Alan now owns 18,260 shares of Precision BioSciences Inc., valued at $16,328 using the latest closing price.

Kelly John Alexander, the Chief Financial Officer of Precision BioSciences Inc., purchase 16,677 shares at $3.08 during a trade that took place back on Mar 17, which means that Kelly John Alexander is holding 36,189 shares at $51,365 based on the most recent closing price.

Stock Fundamentals for DTIL

Current profitability levels for the company are sitting at:

  • -34.11 for the present operating margin

The net margin for Precision BioSciences Inc. stands at -26.49. Equity return is now at value -34.80, with -13.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 4.50.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam